

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)



(10) International Publication Number
WO 2021/126732 A1

(51) International Patent Classification:

A61K 31/435 (2006.01) C07D 217/00 (2006.01)
A61K 31/4353 (2006.01) C07D 401/14 (2006.01)
A61K 31/519 (2006.01) C07D 487/02 (2006.01)

(21) International Application Number:

PCT/US2020/064766

(22) International Filing Date:

14 December 2020 (14.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/949,247 17 December 2019 (17.12.2019) US
62/949,245 17 December 2019 (17.12.2019) US
63/025,608 15 May 2020 (15.05.2020) US

(71) Applicant: MERCK SHARP & DOHME CORP.

[US/US]; 126 East Lincoln Avenue, Rahway, New Jersey
07065-0907 (US).

(72) Inventors; and

(71) Applicants (for US only): MACHACEK, Michelle

[US/US]; 33 Avenue Louis Pasteur, Boston, Massachusetts
02115-5727 (US). ALTMAN, Michael, D. [US/US]; 33
Avenue Louis Pasteur, Boston, Massachusetts 02115-5727
(US). KAWAMURA, Shuhei [JP/US]; 33 Avenue Louis
Pasteur, Boston, Massachusetts 02115-5727 (US). SLO-
MAN, David, L. [US/US]; 33 Avenue Louis Pas-
teur, Boston, Massachusetts 02115-5727 (US). WITTER,
David, J. [US/CA]; 6 Granite Court, Toronto, Ontario M8V
4A4 (CA). GIBEAU, Craig, R. [US/US]; 80 Little Pond
Road, Northborough, Massachusetts 01532 (US).

(74) Common Representative: MERCK SHARP & DOHME

CORP.; 126 East Lincoln Avenue, Rahway, New Jersey
07065-0907 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).





Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: PRMT5 INHIBITORS



(57) Abstract: The present invention provides a compound selected from: and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutical compositions comprising compounds disclosed herein, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

WO 2021/126732 A1